July 3, 2023

Sue Peschin – FDA, CMS, and Alzheimer’s Drugs: What Do American Voters Want?

Sue Peschin – FDA, CMS, and Alzheimer’s Drugs: What Do American Voters Want?

About This Episode

Should Alzheimer’s drugs be treated like all other drugs when it comes to Medicare coverage? The Alliance for Aging Research CEO Sue Peschin and BrainStorm host Meryl Comer dive into polling data that reveals most American voters, regardless of party, disagree with CMS’s policy that will limit access. Their conversation sheds light on how the coverage decision, if it stands, will create not only greater disparities, but also have wide-ranging implications on coverage for other disease-modifying therapies. 

This episode is sponsored by Eisai.

Support the show

BrainStorm Feed

100

2025 Year in Review and Predictions for 2026 with George Vradenburg

George Vradenburg, Chairman and Founder of UsAgainstAlzheimer's, sits down with host Meryl Comer for a comprehensive look at the state of Alzheimer's research, advocacy, and care in 2025.
LISTEN NOW
99

The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer’s Platform (part 2)

In part 2 John Dwyer, CEO of the Global Alzheimer's Platform (GAP), and BrainStorm host Meryl Comer discuss transforming Alzheimer's research and clinical trials.
LISTEN NOW
98

The Future of Alzheimer's Trials: Bringing Cutting-Edge Research to Every Community - John Dwyer, CEO of The Global Alzheimer's Platform

John Dwyer, CEO of the Global Alzheimer's Platform (GAP), highlights GAP's innovations in improving the participant experience through streamlining visits, personalized feedback, and bringing mobile trials directly to small communities.
LISTEN NOW